The BodyLogicMD Network of Physicians Specializing in Hormone Therapy React to KEEPS Study
October, 2012 – Yesterday, the preliminary findings of the Kronos Early Estrogen Prevention Study (KEEPS) were highlighted confirming the safety and efficacy of hormone therapy for the treatment of menopause. The four-year study, although small, is the first in what is expected to be a long line of studies that will not only answer the question, “is hormone therapy safe,” but will also shed light on the safety and efficacy of bioidentical hormone therapies.
BodyLogicMD, the nation’s largest network of highly-trained physicians specializing in bioidentical hormone therapy, has been following the study since the announcement of its design and purpose in 2004. “The results of this study have been highly anticipated and, so far, the preliminary findings are fascinating,” says Dr. Jennifer Landa, Chief Medical Officer of BodyLogicMD, responsible for the education and training of the growing network of physicians, currently boasting more than 50 expert bioidentical hormone doctors. “This long-term study is crucial in refuting the fears initiated by the Women’s Health Initiative and proving that bioidentical hormone therapy is safe and effective for menopause relief and disease prevention.”
This results released yesterday covered the arm of the study comparing the safety and efficacy of oral (synthetic) estrogen or transdermal (bioidentical) estrogen, when combined with micronized (bioidentical) progesterone, in the treatment of menopausal symptoms and risk of disease. The subjects were all females, aged 42 to 58 and within three years of menopause after randomization. The results have yielded positive outcomes for both treatments in comparison to a placebo. Namely, the improvements in the symptoms of menopause, but markers of disease were either unaffected or improved, except in the case of the oral estrogens, which yielded increase triglyceride levels.
There are other branches of the study that are seeking to offer more conclusive evidence on the effectiveness of these forms of hormone therapy in reducing the risk of disease and the impact on older female subjects. The release followed the announcement of these results at the North American Menopause Society (NAMS) meeting in Orlando, Florida. These preliminary results are expected to be published later this year.
Reference: www.bodylogicmd.com
http://revitalifecompoundingpharmacy.com/
https://revitalifedrip.com/
